← Back
NeuroTrials.ai
Neurology Clinical Trial Database

DAYLIGHT

Extended CT angiography versus standard CT angiography for the detection of cardioaortic thrombus in patients with ischaemic stroke and transient ischaemic attack (DAYLIGHT)

Year of Publication: 2025

Authors: Luciano A Sposato, Diana Ayan, Mobeen Ahmed, ..., Rodrigo Bagur

Journal: The Lancet Neurology

Citation: Lancet Neurol. 2025;24:489–499

Link: https://www.thelancet.com/journals/laneu...0104-6/fulltext

PDF: https://www.researchgate.net/profile/Fas...saWNhdGlvbiJ9fQ


Clinical Question

Does extended head-to-heart CT angiography increase detection of cardioaortic thrombus in acute stroke or TIA without delaying treatment?

Bottom Line

Extended CT angiography significantly improves detection of cardioaortic thrombus without delaying stroke care or increasing adverse effects, suggesting a simple and feasible strategy to enhance early cardiac source detection.

Major Points

  • Randomized, blinded-endpoint trial comparing standard vs extended CT angiography in acute stroke/TIA
  • Detection of cardioaortic thrombus significantly higher in extended CT group (8.8% vs. 1.7%; OR 5.70, 95% CI 1.92–16.96, p=0.002)
  • No delay in imaging or acute treatments (median time 21 min vs 20 min, p=0.67)
  • Number needed to screen = 14 for detection of 1 thrombus
  • Additional radiation exposure was minimal (1.2 mSv more)
  • Extended CTA may allow early thrombus detection before it is dissolved by thrombolysis or anticoagulation

Design

Study Type: Randomized, open-label, blinded-endpoint trial

Randomization: 1

Blinding: Blinded outcome adjudication

Enrollment Period: July 17, 2023 – May 6, 2024

Follow-up Duration: ≥30 days

Centers: 1

Countries: Canada

Sample Size: 830

Analysis: Modified intention-to-treat; logistic regression with prespecified and post-hoc sensitivity analyses


Inclusion Criteria

  • Adults ≥18 years
  • Assessed during acute code stroke with suspected ischaemic stroke or TIA

Exclusion Criteria

  • Known allergy or safety concern with iodinated contrast (e.g., severe renal failure)
  • No intravenous access
  • Prior CT angiography before arrival
  • Hemorrhagic stroke on initial CT
  • Stroke deemed unlikely by treating neurologist

Baseline Characteristics

CharacteristicControlActive
Age, median (IQR)78.0 (69.5–84.0)78.0 (68.2–86.0)
Sex - Female54%49%
Sex - Male46%51%
Hypertension70%69%
Diabetes30%32%
Dyslipidemia52%49%
Cancer15%19%
Chronic Kidney Disease14%9%
Heart Failure10%10%
Coronary Artery Disease25%25%
Previous Stroke20%20%
Any Atrial Fibrillation40%41%
Previously Known AF20%27%
New AF on ECG8%13%
New AF on Holter16%5%
New AF on Telemetry17%21%

Arms

FieldExtended CT AngiographyControl
InterventionNon-ECG-gated CTA extended ≥6 cm below carina to image left atrial appendage and heartHead and neck CTA to aortic arch (standard care)
DurationSingle diagnostic scanSingle diagnostic scan

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Detection of confirmed or highly suspected cardioaortic thrombus ≥30 days after qualifying eventPrimary1.7%8.8%0.002
Cardioaortic thrombus, vegetation, or tumourSecondary2.9%9.7%3.570.004
Any cardioembolic source (composite)Secondary30.5%38.5%1.420.07
De novo treatment initiated for detected embolic sourceSecondary13.4%12.4%0.910.75
Time to CTA CompletionAdverse20 min21 min0.67
Radiation Exposure (mSv)Adverse15.016.10.0013
Contrast-Induced NephropathyAdverse10

Subgroup Analysis

No significant interaction across subgroups including age, sex, AF status, or stroke severity


Criticisms

  • Single-centre design may limit external validity
  • Incomplete follow-up with advanced cardiac imaging
  • Possible underdetection or misclassification of thrombi
  • No evaluation of long-term clinical outcomes such as recurrence or mortality

Funding

Western University and the Kathleen and Dr Henry Barnett Chair in Stroke Research

Based on: DAYLIGHT (The Lancet Neurology, 2025)

Authors: Luciano A Sposato, Diana Ayan, Mobeen Ahmed, ..., Rodrigo Bagur

Citation: Lancet Neurol. 2025;24:489–499

Content summarized and formatted by NeuroTrials.ai.